Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies (NCT07484906) | Clinical Trial Compass
WithdrawnPhase 2
Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
Stopped: This is temporary withdrawal as the record was started too soon. It will be reactivated in near future.
0Started 2026-05-01
Plain-language summary
PRE-EMPT will assemble a study group of 150 civilian and Veteran participants from three populations (low risk, intermediate risk, and high risk for self-harm). The investigators will obtain clinical assessments, MRI, and blood levels for circular RNA (circRNA). The teams will then administer three interventions (neurofeedback, transcranial magnetic stimulation, and psilocybin assisted therapy), and repeat the tests above. A team with expertise in artificial intelligence will then use our data to try to find patterns that identify who is at high risk versus low risk with a high degree of accuracy.
Who can participate
Age range18 Years – 69 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18-69 years old
✓. Have been on a stable psychiatric medication regimen for at least four weeks prior to study participation.
Exclusion criteria
✕. A prior history of other central nervous system disease or any history of seizures;
✕. history of psychotic disorders (e.g., schizophrenia, schizoaffective disorder, bipolar disorder type I);
✕. history of current or recent (within two years) substance/alcohol use disorder, with the exception of tobacco use disorder;
✕. meet criteria for Very High risk of suicide, or require inpatient hospital-level care for psychiatric reasons at time of consent, to reduce exacerbation of risk of harm to self during study;
✕. presence of any implanted metal or electrical device (e.g. pacemaker);
✕. recent medical hospitalization (within three weeks);
✕. any condition that would prevent the participant from completing the protocol, such as significant agitation;
What they're measuring
1
Scale of Suicidal Ideation
Timeframe: Baseline (Day 1) to Post-Treatment Visit (Month 6)